All In Biotech

Drug Trial Radar · NCT03283826

Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis

A Phase 1/2, Two-part, Open-label Dose-escalation and Double-blind, Placebo-controlled Dose-expansion Study With an Open-label Extension to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis

Last checked: Nov 19, 2026Latest source record: Feb 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingRandomized with 134 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

134

Actual

Start

Oct 19, 2017

Primary completion

Nov 9, 2023

Study completion Jan 17, 2024

Sponsor

Lead sponsor
Atara BiotherapeuticsIndustry
Sponsor type
Industry
First posted
Sep 14, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and tolerability of ATA188 as a monotherapy in Parts 1 and 2, to determine the recommended Part 2 dose (RP2D) of ATA188 as monotherapy in Part 1, and to evaluate the effect of ATA188 treatment on clinical disability, as assessed by confirmed Expanded Disability Status Scale (EDSS) improvement at 12 months in Part 2 in participants with progressive forms of multiple sclerosis (MS) (primary progressive multiple sclerosis \[PPMS\] and secondary progressive multiple sclerosis \[SPMS\]).

Conditions

  • Primary Progressive Multiple Sclerosis
  • Secondary Progressive Multiple Sclerosis

Interventions

  • ATA188Biological

    ATA188 is being investigated as an off-the-shelf, allogeneic T-cell immunotherapy for the treatment of EBV+ progressive multiple sclerosis.

  • PlaceboDrug

    Placebo matching to ATA188

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Incidence of adverse eventsTime frame: At 12 months after the first dose of study drug
  2. Part 1: Incidence of clinically significant changes in laboratory tests, electrocardiograms (ECGs), and vital signsTime frame: At 12 months after the first dose of study drug
  3. Part 1: Recommended Part 2 dose of ATA188 monotherapyTime frame: Day 1 to Day 35 of Cycle 1 for each participant in dose escalation part (approximately 1 year)
  4. Part 2: Percentage of participants with confirmed expanded disability status scale (EDSS) improvement at 12 monthsTime frame: At 12 months after the first dose of study drug

Locations

31 sites in 3 countries. Site status is shown where the registry gives one.

  • University of California, San Diego

    La Jolla, California

  • Kaiser Permanente MS Clinic Los Angeles

    Los Angeles, California

  • Stanford University

    Palo Alto, California

  • University of California San Francisco

    San Francisco, California

  • University of Colorado

    Aurora, Colorado

  • Advanced Neurology

    Fort Collins, Colorado

  • Neurology Associates, PA-Maitland

    Maitland, Florida

  • University of South Florida, Morsani College of Medicine

    Tampa, Florida

  • Fort Wayne Neurological Center

    Fort Wayne, Indiana

  • University of Kansas Medical Center KUMC - Multiple Sclerosis MS Center

    Kansas City, Kansas

  • Ochsner Clinic Foundation

    New Orleans, Louisiana

  • Dragonfly Research

    Wellesley, Massachusetts

  • Washington University in St. Louis

    St Louis, Missouri

  • Dent Neurologic Institute

    Amherst, New York

  • Columbia University Medical Center-The Neurological Institute of New York

    New York, New York

  • University of Rochester Medical Center - URMC

    Rochester, New York

  • PMG Research of Piedmont Healthcare

    Mooresville, North Carolina

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • Premier Neurology P.C.

    Greer, South Carolina

  • Advanced Neurosciences Institute ANI - Franklin

    Franklin, Tennessee

  • Vanderbilt Comprehensive Multiple Sclerosis Center

    Nashville, Tennessee

  • The University of Texas Health Science Center at Houston

    Houston, Texas

  • MS Center of Greater Washington

    Vienna, Virginia

  • Inland Northwest Research LLC

    Spokane, Washington

  • Medical College of Wisconsin

    Milwaukee, Wisconsin

  • Liverpool Hospital

    Liverpool, New South Wales, Australia

  • Royal Brisbane and Women's Hospital

    Brisbane, Queensland, Australia

  • Griffith University, School of Medicine

    Southport, Queensland, Australia

  • Fraser Health Multiple Sclerosis Clinic

    Burnaby, British Columbia, Canada

  • Unity Health Toronto/St. Michael's Hospital

    Toronto, Ontario, Canada

  • Recherche Sepmus Inc.

    Greenfield Park, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.